Журнал кардиореспираторных исследований 2026. №2/3

Тема статьи

Podagra va giperurikemiya holatida kardiorenal zararlanishlar hamda metabolik sindromning klinik, immunologik va genetik xususiyatlari (72-77)

Авторы

D.R. Tairov, D.H. Berdiyev

Учреждение

Samarqand davlat tibbiyot universiteti

Аннотация

Tadqiqot maqsadi: Podagra kasalligi va giperurikemiya holatida bemorlarda kardiorenal zararlanishlar va metabolik sindromning klinik, immunologik hamda genetik xususiyatlarini kompleks o'rganish. Material va usullar: Tadqiqotga podagra bilan kasallangan 98 nafar bemor kiritildi. Bemorlar yosh ko'rsatkichlari, kasallik kechishi va kardiovaskulyar patologiyalar mavjudligiga qarab guruhlarga ajratildi. Barcha bemorlarda klinik, antropometrik, laborator (siydik kislotasi, lipid profili, kreatinin, SRO, sitokinlar), immunologik (IL-1β, IL-6, TNF-α, sVCAM-1) va genetik (SLC2A9, ABCG2 gen polimorfizmi) tekshiruvlar o'tkazildi. Kardiorenal zararlanishlarni baholash uchun exokardiografiya, kunlik AQB monitoringi va buyrak funksiyasi (KFT, albuminuriya) aniqlandi. Natijalar: Bemorlarning 78,6% da arterial gipertenziya, 62,2% da yurak ishemik kasalligi, 41,8% da surunkali buyrak yetishmovchiligi aniqlangan. Metabolik sindrom komponentlari yuqori chastotada uchragan: abdominal semizlik (71,4%), dislipidemiya (68,3%), giperglikemiya (28,6%). Immunologik tekshiruvlarda yallig'lanishga qarshi sitokinlar (IL-1β, IL-6, TNF-α) darajasining sezilarli oshishi qayd etilgan. SLC2A9 genining rs12498742 varianti va ABCG2 genining rs2231142 polimorfizmi giperurikemiya va kardiorenal asoratlar rivojlanishi bilan bog'liqligi aniqlangan. Xulosa: Podagra bilan kasallanish va giperurikemiya holatida, bemorlarda kardiorenal zararlanishlar yuqori chastotada uchraydi va metabolik sindrom komponentlari, immun yallig'lanish faolligi hamda genetik polimorfizmlar bilan chambarchas bog'liq.

Ключевые слова

podagra, giperurikemiya, kardiorenal sindrom, metabolik sindrom, sitokinlar, gen polimorfizmi, SLC2A9, ABCG2.

Литературы

1. Dalbeth N., Gosling A.L., Gaffo A., Abhishek A. Gout // Lancet. – 2021. – Vol. 397(10287). – P. 1843-1855. 2. Richette P., Doherty M., Pascual E., et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout // Ann Rheum Dis. – 2020. – Vol. 79(1). – P. 31-38. 3. Borghi C., Agabiti-Rosei E., Johnson R.J., et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease // Eur J Intern Med. – 2020. – Vol. 80. – P. 1-11. 4. Johnson R.J., Bakris G.L., Borghi C., et al. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop // Am J Kidney Dis. – 2019. – Vol. 73(6). – P. 852-865. 5. Feig D.I., Kang D.H., Johnson R.J. Uric acid and cardiovascular risk // N Engl J Med. – 2021. – Vol. 384(11). – P. 1021-1032. 6. Kanbay M., Jensen T., Solak Y., et al. Uric acid in metabolic syndrome: From an innocent bystander to a central player // Eur J Intern Med. – 2021. – Vol. 89. – P. 3-11. 7. Ronco C., McCullough P., Anker S.D., et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative // Eur Heart J. – 2020. – Vol. 41(12). – P. 1245-1256. 8. Saito Y., Tanaka A., Node K., Kobayashi Y. Uric acid and cardiovascular disease: A clinical review // J Cardiol. – 2021. – Vol. 78(1). – P. 51-57. 9. Pontremoli R., Viazzi F. Uric acid and hypertension: A clinical review // J Nephrol. – 2022. – Vol. 35(4). – P. 1155-1165. 10. Wang Y., Li Y., Liu C., et al. Uric acid and endothelial dysfunction: A molecular perspective // Front Med. – 2023. – Vol. 10. – P. 1125678. 11. So A.K., Martinon F. Inflammation in gout: mechanisms and therapeutic targets // Nat Rev Rheumatol. – 2021. – Vol. 17(8). – P. 459- 472. 12. Cavalcanti N.G., Marques C.D.L., Lins E., et al. Cytokine profile in gout: Inflammation driven by IL-1, IL-6 and TNF-α // Clin Rheumatol. – 2022. – Vol. 41(5). – P. 1489-1498. 13. Perez-Ruiz F., Castillo E., Chinchilla S.P., et al. Clinical manifestations and diagnosis of gout // Rheum Dis Clin North Am. – 2022. – Vol. 48(4). – P. 789-804. 14. Major T.J., Dalbeth N., Stahl E.A., Merriman T.R. An update on the genetics of hyperuricaemia and gout // Nat Rev Rheumatol. – 2022. – Vol. 18(7). – P. 414-430. 15. Merriman T.R. An update on the genetic architecture of hyperuricemia and gout // Arthritis Res Ther. – 2021. – Vol. 23(1). – P. 97. 16. Nakayama A., Nakatochi M., Kawamura Y., et al. SLC2A9 rs12498742 polymorphism and gout susceptibility: A meta-analysis // Rheumatology. – 2023. – Vol. 62(3). – P. 1124-1133. 17. Matsuo H., Yamamoto K., Nakaoka H., et al. ABCG2 rs2231142 variant and gout risk: A systematic review and meta-analysis // Sci Rep. – 2022. – Vol. 12(1). – P. 4567. 18. Thottam G.E., Krasnokutsky S., Pillinger M.H. Gout and metabolic syndrome: a tangled web // Curr Rheumatol Rep. – 2021. – Vol. 23(5). – P. 31. 19. Singh J.A., Cleveland J.D. Gout and the risk of incident metabolic syndrome: A cohort study // Arthritis Res Ther. – 2022. – Vol. 24(1). – P. 112. 20. Vazquez-Mellado J., Cruz J., Guzman S., et al. Metabolic syndrome and its components in patients with gout // J Clin Rheumatol. – 2021. – Vol. 27(3). – P. 98-104. 21. Tairov D.R., Berdiev D.H. Gout: Immunological and genetic characteristics of the disease // Academic Journal. – 2024. – Vol. 3(12). – P. 45-52. 22. Tairov D.R., Berdiev D.H. Characteristics of Cardiohemodynamic Disorders in Gout Disease // Scientific Progress. – 2021. – Vol. 2(3). – P. 112-118. 23. Tairov D.R., Berdiev D.H. . Medication and Non-Medication Methods to Eliminate Hyperuricemia in Gout // Science and Education. – 2023. – Vol. 4(5). – P. 234-242. 24. Tairov D.R., Berdiev D.H. Characteristics of Heart Functional Disorders in Gout Disease // Galaxy International Interdisciplinary Research Journal. – 2022. – Vol. 10(5). – P. 178-186. 25. Tairov E.S., Tairov D.R. Metabolic Syndrome in Gout: Its Relationship with Renal Functional Disorders // Questions of Science and Education. – 2019. – No. 28(77). – P. 45-52. 26. Tairov D.R., Makhmudova H.D. Cardiovascular Damage in Patients with Gout // Scientific Progress. – 2021. – Vol. 2(2). – P. 242-249. 27. Yarmukhamedova S.Kh. ., Kamolova D.Zh. Study of Myocardial Geometry in Hypertensive Patients Using Echocardiography // Achievements of Science and Education. – 2019. – No. 12(53). – P. 34-41. 28. Eliseev M.S., Barskova V.G., Nasonov V.A. Clinical Significance of Metabolic Syndrome in Gout // Clinical Gerontology. – 2021. – Vol. 27(3-4). – P. 29-35. 29. Tairov E.S., Tairov D.R., Solovyev S.K. Gout: Diagnosis and Treatment. – Tashkent, 2020. – 184 p. 30. Jalal D.I., Chonchol M., Chen W., Targher G. Uric Acid as a Therapeutic Target in CKD // Am J Kidney Dis. – 2022. – Vol. 79(5). – P. 134-146.